Lindahl acted as legal advisor to Corline Biomedical

Through the agreement, Imperative Care is given the exclusive right to use CHS™ in all types of neurovascular products given a certain level of compensation. Corline undertakes to supply CHS™-coated products according to defined specifications, but also to assist in further development and market registration of the current product. In addition, Corline will participate in the development of additional CHS™-coated products within the indication area. These products have the potential to generate revenue for Corline of approximately SEK 150 million per year and a total of more than SEK 1 billion.

Lindahl's team consisted of Hugo Norlén and Erika Svensson.

Corline's press release (in Swedish) is available here.